Vaxcyte, Inc. (NASDAQ:PCVX) Receives Average Rating of “Moderate Buy” from Analysts

Vaxcyte, Inc. (NASDAQ:PCVX) has earned a consensus recommendation of “Moderate Buy” from the ten ratings firms that are covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, seven have issued a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $97.8333.

A number of equities analysts have recently weighed in on PCVX shares. Leerink Partners set a $77.00 price target on Vaxcyte and gave the stock an “outperform” rating in a report on Wednesday, November 19th. The Goldman Sachs Group began coverage on Vaxcyte in a research report on Friday, September 12th. They set a “neutral” rating and a $38.00 price objective for the company. BTIG Research restated a “buy” rating and issued a $85.00 target price on shares of Vaxcyte in a report on Monday, November 10th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vaxcyte in a research note on Tuesday, October 14th.

Institutional Investors Weigh In On Vaxcyte

A number of institutional investors have recently bought and sold shares of the stock. AlphaQuest LLC purchased a new position in shares of Vaxcyte in the 1st quarter worth about $33,000. BI Asset Management Fondsmaeglerselskab A S acquired a new stake in Vaxcyte during the 1st quarter worth approximately $35,000. Allworth Financial LP increased its position in Vaxcyte by 148.9% during the 3rd quarter. Allworth Financial LP now owns 1,222 shares of the company’s stock worth $44,000 after purchasing an additional 731 shares in the last quarter. Aster Capital Management DIFC Ltd purchased a new position in Vaxcyte in the third quarter valued at approximately $45,000. Finally, CIBC Private Wealth Group LLC lifted its position in Vaxcyte by 22,500.0% during the third quarter. CIBC Private Wealth Group LLC now owns 1,356 shares of the company’s stock valued at $49,000 after buying an additional 1,350 shares in the last quarter. 96.78% of the stock is currently owned by hedge funds and other institutional investors.

Vaxcyte Trading Up 6.2%

Shares of PCVX opened at $46.42 on Monday. Vaxcyte has a 12-month low of $27.66 and a 12-month high of $93.77. The stock has a market cap of $6.08 billion, a P/E ratio of -9.59 and a beta of 1.28. The company has a 50-day moving average of $45.06 and a two-hundred day moving average of $37.92.

Vaxcyte (NASDAQ:PCVX) last issued its quarterly earnings data on Tuesday, November 4th. The company reported ($1.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.27) by ($0.29). During the same period in the previous year, the business posted ($0.83) earnings per share. As a group, analysts forecast that Vaxcyte will post -4.21 EPS for the current fiscal year.

About Vaxcyte

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.